Medivation shares rise in pre-market on positive results in drug trial
Medivation Inc. (Nasdaq:MDVN) is up more than 3% in pre-market trading today after the biopharmaceutical company announced after the close on Monday that Dimebon, an investigational drug, had improved brain function in patients with mild forms of Huntington’s disease during Phase 2 trials. Huntington’s affects brain cells and leads to uncontrollable movements and loss of cognitive function. The drug is now being tested on patients with Alzheimer’s, the San Francisco-based company said.
Ahead of the opening bell today, Medivation shares are at $12.50, up $0.44 or 3.65%, from Monday’s close.
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
